These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24938627)

  • 1. Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study.
    Vermond RA; Crijns HJ; Tijssen JG; Alings AM; Van den Berg MP; Hillege HL; Van Veldhuisen DJ; Van Gelder IC; Rienstra M;
    Europace; 2014 Oct; 16(10):1417-25. PubMed ID: 24938627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a new simple scale to measure symptoms in atrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale.
    Dorian P; Guerra PG; Kerr CR; O'Donnell SS; Crystal E; Gillis AM; Mitchell LB; Roy D; Skanes AC; Rose MS; Wyse DG
    Circ Arrhythm Electrophysiol; 2009 Jun; 2(3):218-24. PubMed ID: 19808471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of atrial fibrillation monitor characteristics to predict severity of symptoms of atrial fibrillation.
    Patel N; Chung EH; Mounsey JP; Schwartz JD; Pursell I; Gehi AK
    Am J Cardiol; 2014 May; 113(10):1674-8. PubMed ID: 24698459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study.
    Mulder BA; Van Veldhuisen DJ; Crijns HJ; Tijssen JG; Hillege HL; Alings M; Rienstra M; Groenveld HF; Van den Berg MP; Van Gelder IC;
    Eur J Heart Fail; 2013 Nov; 15(11):1311-8. PubMed ID: 23759284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure.
    Frasure-Smith N; Lespérance F; Habra M; Talajic M; Khairy P; Dorian P; Roy D;
    Circulation; 2009 Jul; 120(2):134-40, 3p following 140. PubMed ID: 19564557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low atrial fibrillatory rate is associated with poor outcome in patients with mild to moderate heart failure.
    Platonov PG; Cygankiewicz I; Stridh M; Holmqvist F; Vazquez R; Bayes-Genis A; McNitt S; Zareba W; de Luna AB;
    Circ Arrhythm Electrophysiol; 2012 Feb; 5(1):77-83. PubMed ID: 22235036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stroke prediction using mean platelet volume in patients with atrial fibrillation.
    Ha SI; Choi DH; Ki YJ; Yang JS; Park G; Chung JW; Koh YY; Chang KS; Hong SP
    Platelets; 2011; 22(6):408-14. PubMed ID: 21599611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation).
    Groenveld HF; Tijssen JG; Crijns HJ; Van den Berg MP; Hillege HL; Alings M; Van Veldhuisen DJ; Van Gelder IC;
    J Am Coll Cardiol; 2013 Feb; 61(7):741-8. PubMed ID: 23410544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study.
    Mulder BA; Van Veldhuisen DJ; Crijns HJ; Tijssen JG; Hillege HL; Alings M; Rienstra M; Van den Berg MP; Van Gelder IC;
    Heart Rhythm; 2014 Sep; 11(9):1543-50. PubMed ID: 24924587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
    J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
    Freeman JV; Simon DN; Go AS; Spertus J; Fonarow GC; Gersh BJ; Hylek EM; Kowey PR; Mahaffey KW; Thomas LE; Chang P; Peterson ED; Piccini JP;
    Circ Cardiovasc Qual Outcomes; 2015 Jul; 8(4):393-402. PubMed ID: 26058720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis of transient new-onset atrial fibrillation during vascular surgery.
    Winkel TA; Schouten O; Hoeks SE; Verhagen HJ; Bax JJ; Poldermans D
    Eur J Vasc Endovasc Surg; 2009 Dec; 38(6):683-8. PubMed ID: 19683947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The change in the atrial fibrillation type as a prognosis marker in a community study: long-term data from AFBAR (Atrial Fibrillation in the BARbanza) study.
    Vidal-Perez R; Otero-Raviña F; Lado-López M; Turrado-Turrado V; Rodríguez-Moldes E; Gómez-Vázquez JL; de Frutos-de Marcos C; de Blas-Abad P; Besada-Gesto R; Gonzalez-Juanatey JR;
    Int J Cardiol; 2013 Oct; 168(3):2146-52. PubMed ID: 23452888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial fibrillation predicts appropriate shocks in primary prevention implantable cardioverter-defibrillator patients.
    Smit MD; Van Dessel PF; Rienstra M; Nieuwland W; Wiesfeld AC; Tan ES; Anthonio RL; Van Veldhuisen DJ; Van Gelder IC
    Europace; 2006 Aug; 8(8):566-72. PubMed ID: 16864611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.
    O'Meara E; Khairy P; Blanchet MC; de Denus S; Pedersen OD; Levesque S; Talajic M; Ducharme A; White M; Racine N; Rouleau JL; Tardif JC; Roy D;
    Circ Heart Fail; 2012 Sep; 5(5):586-93. PubMed ID: 22798522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymptomatic persistent atrial fibrillation and outcome: results of the RACE study.
    Rienstra M; Vermond RA; Crijns HJ; Tijssen JG; Van Gelder IC;
    Heart Rhythm; 2014 Jun; 11(6):939-45. PubMed ID: 24632222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study.
    Groenveld HF; Crijns HJ; Van den Berg MP; Van Sonderen E; Alings AM; Tijssen JG; Hillege HL; Tuininga YS; Van Veldhuisen DJ; Ranchor AV; Van Gelder IC;
    J Am Coll Cardiol; 2011 Oct; 58(17):1795-803. PubMed ID: 21996393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left ventricular diastolic dysfunction in atrial fibrillation: predictors and relation with symptom severity.
    Kosiuk J; Van Belle Y; Bode K; Kornej J; Arya A; Rolf S; Husser D; Hindricks G; Bollmann A
    J Cardiovasc Electrophysiol; 2012 Oct; 23(10):1073-7. PubMed ID: 22672521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial.
    Hohnloser SH; Shestakovska O; Eikelboom J; Franzosi MG; Tan RS; Zhu J; Yusuf S; Connolly SJ
    Eur Heart J; 2013 Sep; 34(35):2752-9. PubMed ID: 23892201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.
    Disertori M; Lombardi F; Barlera S; Maggioni AP; Favero C; Franzosi MG; Lucci D; Staszewsky L; Fabbri G; Quintarelli S; Bianconi L; Latini R
    Am Heart J; 2011 Aug; 162(2):382-9. PubMed ID: 21835301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.